Inspire Investing LLC Sells 41,176 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Inspire Investing LLC reduced its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 63.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 23,491 shares of the biotechnology company’s stock after selling 41,176 shares during the quarter. Inspire Investing LLC’s holdings in ADMA Biologics were worth $403,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. State Street Corp boosted its stake in shares of ADMA Biologics by 61.4% during the third quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company’s stock valued at $259,970,000 after purchasing an additional 4,945,063 shares in the last quarter. Geode Capital Management LLC boosted its position in ADMA Biologics by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 5,381,985 shares of the biotechnology company’s stock valued at $107,606,000 after acquiring an additional 137,989 shares in the last quarter. Perpetual Ltd bought a new stake in ADMA Biologics during the 4th quarter valued at $62,300,000. Assenagon Asset Management S.A. increased its holdings in shares of ADMA Biologics by 2.7% in the 3rd quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company’s stock valued at $69,454,000 after acquiring an additional 92,281 shares during the period. Finally, Lord Abbett & CO. LLC bought a new position in shares of ADMA Biologics in the 3rd quarter worth $61,858,000. 75.68% of the stock is owned by hedge funds and other institutional investors.

ADMA Biologics Trading Down 3.0 %

Shares of NASDAQ:ADMA opened at $16.08 on Friday. The business’s 50-day moving average is $18.56 and its 200 day moving average is $17.46. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. ADMA Biologics, Inc. has a 1 year low of $5.02 and a 1 year high of $23.64. The firm has a market capitalization of $3.80 billion, a P/E ratio of 57.43 and a beta of 0.76.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.13 by $0.02. The firm had revenue of $119.84 million for the quarter, compared to the consensus estimate of $107.25 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. During the same quarter in the prior year, the company posted $0.01 earnings per share. On average, research analysts predict that ADMA Biologics, Inc. will post 0.51 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. Raymond James lifted their target price on ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a research note on Friday, November 8th. HC Wainwright lifted their price objective on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, November 8th.

Insider Activity

In related news, CFO Brad L. Tade sold 15,000 shares of the firm’s stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total transaction of $317,250.00. Following the completion of the transaction, the chief financial officer now owns 199,433 shares of the company’s stock, valued at $4,218,007.95. This trade represents a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 3.70% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.